In November 2003, Canada introduced legislation to amend the Patent Act so that manufacturers could obtain licences to make generic versions of patented pharmaceutical products for export to countries lacking sufficient capacity to produce their own. This article provides an overview of recent global developments leading up to Canada’s initiative, as well as an analysis of Bill C-56 itself.

Download